| pubmed-article:20625124 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20625124 | lifeskim:mentions | umls-concept:C0023467 | lld:lifeskim |
| pubmed-article:20625124 | lifeskim:mentions | umls-concept:C0242596 | lld:lifeskim |
| pubmed-article:20625124 | lifeskim:mentions | umls-concept:C0220901 | lld:lifeskim |
| pubmed-article:20625124 | pubmed:issue | 23 | lld:pubmed |
| pubmed-article:20625124 | pubmed:dateCreated | 2010-8-9 | lld:pubmed |
| pubmed-article:20625124 | pubmed:abstractText | To evaluate the prognostic impact of minimal residual disease (MRD) in patients with acute myeloid leukemia (AML) expressing the CBFB-MYH11 fusion transcript. | lld:pubmed |
| pubmed-article:20625124 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20625124 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20625124 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20625124 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20625124 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20625124 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20625124 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20625124 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20625124 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:20625124 | pubmed:issn | 1527-7755 | lld:pubmed |
| pubmed-article:20625124 | pubmed:author | pubmed-author:ReimerPeterP | lld:pubmed |
| pubmed-article:20625124 | pubmed:author | pubmed-author:GanserArnoldA | lld:pubmed |
| pubmed-article:20625124 | pubmed:author | pubmed-author:DöhnerHartmut... | lld:pubmed |
| pubmed-article:20625124 | pubmed:author | pubmed-author:NachbaurDavid... | lld:pubmed |
| pubmed-article:20625124 | pubmed:author | pubmed-author:DuJuanJ | lld:pubmed |
| pubmed-article:20625124 | pubmed:author | pubmed-author:KrauterJürgen... | lld:pubmed |
| pubmed-article:20625124 | pubmed:author | pubmed-author:FröhlingStefa... | lld:pubmed |
| pubmed-article:20625124 | pubmed:author | pubmed-author:SchollClaudia... | lld:pubmed |
| pubmed-article:20625124 | pubmed:author | pubmed-author:SchlenkRichar... | lld:pubmed |
| pubmed-article:20625124 | pubmed:author | pubmed-author:DöhnerKonstan... | lld:pubmed |
| pubmed-article:20625124 | pubmed:author | pubmed-author:BullingerLars... | lld:pubmed |
| pubmed-article:20625124 | pubmed:author | pubmed-author:CorbaciogluAn... | lld:pubmed |
| pubmed-article:20625124 | pubmed:author | pubmed-author:EiwenKarinaK | lld:pubmed |
| pubmed-article:20625124 | pubmed:author | pubmed-author:RummelMathias... | lld:pubmed |
| pubmed-article:20625124 | pubmed:author | pubmed-author:DerigsHans-Gü... | lld:pubmed |
| pubmed-article:20625124 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20625124 | pubmed:day | 10 | lld:pubmed |
| pubmed-article:20625124 | pubmed:volume | 28 | lld:pubmed |
| pubmed-article:20625124 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20625124 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20625124 | pubmed:pagination | 3724-9 | lld:pubmed |
| pubmed-article:20625124 | pubmed:meshHeading | pubmed-meshheading:20625124... | lld:pubmed |
| pubmed-article:20625124 | pubmed:meshHeading | pubmed-meshheading:20625124... | lld:pubmed |
| pubmed-article:20625124 | pubmed:meshHeading | pubmed-meshheading:20625124... | lld:pubmed |
| pubmed-article:20625124 | pubmed:meshHeading | pubmed-meshheading:20625124... | lld:pubmed |
| pubmed-article:20625124 | pubmed:meshHeading | pubmed-meshheading:20625124... | lld:pubmed |
| pubmed-article:20625124 | pubmed:meshHeading | pubmed-meshheading:20625124... | lld:pubmed |
| pubmed-article:20625124 | pubmed:meshHeading | pubmed-meshheading:20625124... | lld:pubmed |
| pubmed-article:20625124 | pubmed:meshHeading | pubmed-meshheading:20625124... | lld:pubmed |
| pubmed-article:20625124 | pubmed:meshHeading | pubmed-meshheading:20625124... | lld:pubmed |
| pubmed-article:20625124 | pubmed:meshHeading | pubmed-meshheading:20625124... | lld:pubmed |
| pubmed-article:20625124 | pubmed:meshHeading | pubmed-meshheading:20625124... | lld:pubmed |
| pubmed-article:20625124 | pubmed:meshHeading | pubmed-meshheading:20625124... | lld:pubmed |
| pubmed-article:20625124 | pubmed:meshHeading | pubmed-meshheading:20625124... | lld:pubmed |
| pubmed-article:20625124 | pubmed:meshHeading | pubmed-meshheading:20625124... | lld:pubmed |
| pubmed-article:20625124 | pubmed:meshHeading | pubmed-meshheading:20625124... | lld:pubmed |
| pubmed-article:20625124 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20625124 | pubmed:articleTitle | Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia. | lld:pubmed |
| pubmed-article:20625124 | pubmed:affiliation | University Hospital of Ulm, Ulm, Germany. | lld:pubmed |
| pubmed-article:20625124 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20625124 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:20625124 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
